MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells

Open Access

Peer-reviewed

Research Article

Ziqiang Zhu ,

Contributed equally to this work with: Ziqiang Zhu, Jinshan Tang

Affiliation Department of Orthopaedics, the Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, JiangSu Province, China
⨯
Jinshan Tang ,

Contributed equally to this work with: Ziqiang Zhu, Jinshan Tang

Affiliation Department of Orthopedics, Affiliated Huai'an Hospital of Xuzhou Medical College, Huaian, JiangSu Province, China
⨯
Jianqiang Wang,

Affiliation Department of Orthopaedics, the Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, JiangSu Province, China
⨯
Gang Duan,

Affiliation Department of Orthopaedics, the Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, JiangSu Province, China
⨯
Lei Zhou,

Affiliation Department of Orthopaedics, the Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, JiangSu Province, China
⨯
Xiaoqing Zhou

* E-mail: xqzhou_xz@163.com

Affiliation Department of Orthopedics, Affiliated Huai'an Hospital of Xuzhou Medical College, Huaian, JiangSu Province, China
⨯

Reader Comments (0)

Osteosarcoma
Is the Subject Area "Osteosarcoma" applicable to this article?

Thanks for your feedback.
Osteosarcoma cells
Is the Subject Area "Osteosarcoma cells" applicable to this article?

Thanks for your feedback.
MicroRNAs
Is the Subject Area "MicroRNAs" applicable to this article?

Thanks for your feedback.
Transfection
Is the Subject Area "Transfection" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cell migration
Is the Subject Area "Cell migration" applicable to this article?

Thanks for your feedback.